Compare Spyre Therapeutics Inc. Common Stock (SYRE) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Spyre Therapeutics Inc. Common Stock vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Spyre Therapeutics Inc. Common Stock trades at $78.35 (market cap $7.35B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $48.6 (market cap $73.20B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is far larger — about 10× Spyre Therapeutics Inc. Common Stock's market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Spyre Therapeutics Inc. Common Stock for 0 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 92 Days on average.
| SYRE | VTIP | |
|---|---|---|
Market Cap | $7.35B | $73.20B |
Volume | 1,624,631 | 3,980,495 |
Sector | Health | — |
52-Week High | $108.92 | $50.46 |
52-Week Low | $22.18 | $48.38 |
Typical Hold Time | 0 Days | 92 Days |
Enterprise Value | $6.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
VTIP, the Vanguard Short-Term Inflation-Protected Securities ETF, trades at $48.46, down slightly by 0.06% on the day. The technical picture is bearish based on moving averages, with oscillators neutral. Recent news highlights its role as an inflation hedge amid rising energy prices and Fed rate hikes, with institutional buying noted. Key support is at $48, resistance at $49.
The outlook for VTIP is cautious; it offers inflation protection but faces headwinds from persistent high rates. Risks include interest rate sensitivity and inflation volatility. Analyst sentiment is mixed, with some seeing value in short-duration TIPS, but the bearish technical trend suggests near-term pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
